{"data":[{"accessionNo":"0001231919-26-000926","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"OVID THERAPEUTICS INC.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"RA Capital Healthcare Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":19549271,"percentOfClass":9.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001231919-26-000926","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"OVID THERAPEUTICS INC.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"RA Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":19549271,"percentOfClass":9.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001231919-26-000926","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"OVID THERAPEUTICS INC.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Peter Kolchinsky","reportingCik":null,"personType":"HC,IN","sharesOwned":19549271,"percentOfClass":9.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001231919-26-000926","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"OVID THERAPEUTICS INC.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Rajeev Shah","reportingCik":null,"personType":"HC,IN","sharesOwned":19549271,"percentOfClass":9.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001580642-26-005303","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Eventide Asset Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":11812241,"percentOfClass":6.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001580642-26-005303","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Finny Kuruvilla, M.D., Ph. D.","reportingCik":null,"personType":"HC,IN","sharesOwned":11812241,"percentOfClass":6.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001580642-26-005303","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Robin C. John","reportingCik":null,"personType":"HC,IN","sharesOwned":11812241,"percentOfClass":6.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001104659-26-097342","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Daniel Schneeberger","reportingCik":null,"personType":"HC,IN","sharesOwned":9559979,"percentOfClass":5.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001104659-26-097342","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"ADAR1 Capital Management, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":9559979,"percentOfClass":5.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001172661-26-003432","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Dmitry Balyasny","reportingCik":null,"personType":"HC,IN","sharesOwned":9313341,"percentOfClass":4.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001172661-26-003432","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BALYASNY ASSET MANAGEMENT L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":9313341,"percentOfClass":4.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001172661-26-003432","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BAM GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":9313341,"percentOfClass":4.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001172661-26-003432","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Balyasny Asset Management Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":9313341,"percentOfClass":4.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001172661-26-003432","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Dames GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":9313341,"percentOfClass":4.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001104659-26-097342","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"ADAR1 Capital Management GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":9122588,"percentOfClass":4.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001011438-26-000510","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Affinity Asset Advisors, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":15143728,"percentOfClass":7.9,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001011438-26-000510","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Michael Cho","reportingCik":null,"personType":"IN,HC","sharesOwned":15143728,"percentOfClass":7.9,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0002012383-26-002922","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":10822672,"percentOfClass":5.8,"filedAt":"2026-07-29","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001623632-26-000990","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"J. Christopher Donahue","reportingCik":null,"personType":"IN","sharesOwned":7737166,"percentOfClass":4.15,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001623632-26-000990","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"Ann C. Donahue","reportingCik":null,"personType":"IN","sharesOwned":7737166,"percentOfClass":4.15,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001623632-26-000990","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"Thomas R. Donahue","reportingCik":null,"personType":"IN","sharesOwned":7737166,"percentOfClass":4.15,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001623632-26-000990","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"Voting Shares Irrevocable Trust","reportingCik":null,"personType":"OO","sharesOwned":7737166,"percentOfClass":4.15,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001623632-26-000990","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"Federated Hermes, Inc.","reportingCik":null,"personType":"HC","sharesOwned":7737166,"percentOfClass":4.15,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0000919574-26-003209","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Alex Silverstein","reportingCik":null,"personType":"HC,IN","sharesOwned":18031333,"percentOfClass":9.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0000919574-26-003209","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Sirenia Capital Management LP","reportingCik":null,"personType":"IA,PN","sharesOwned":18031333,"percentOfClass":9.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001580642-26-003200","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Robin C. John","reportingCik":null,"personType":"HC,IN","sharesOwned":12773577,"percentOfClass":7.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001580642-26-003200","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Finny Kuruvilla, M.D., Ph. D.","reportingCik":null,"personType":"HC,IN","sharesOwned":12773577,"percentOfClass":7.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001580642-26-003200","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Eventide Asset Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":12773577,"percentOfClass":7.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001193125-26-225184","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Dames GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":7029223,"percentOfClass":5.33,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001193125-26-225184","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Balyasny Asset Management L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":7029223,"percentOfClass":5.33,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001193125-26-225184","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"BAM GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":7029223,"percentOfClass":5.33,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001193125-26-225184","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Balyasny Asset Management Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":7029223,"percentOfClass":5.33,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001193125-26-225184","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Dmitry Balyasny","reportingCik":null,"personType":"HC,IN","sharesOwned":7029223,"percentOfClass":5.33,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0000919574-26-003481","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":1903943,"percentOfClass":1.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0000919574-26-003481","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1903943,"percentOfClass":1.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0000919574-26-003481","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":1903943,"percentOfClass":1.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001011438-26-000317","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Affinity Asset Advisors, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":15635484,"percentOfClass":9.1,"filedAt":"2026-05-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001011438-26-000317","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":"690469101","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Michael Cho","reportingCik":null,"personType":"IN,HC","sharesOwned":15635484,"percentOfClass":9.1,"filedAt":"2026-05-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001256153-26-000006","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001636651","issuerName":"OVID THERAPEUTICS INC.","ticker":"OVID","cusip":"690469101","securityClass":"COMMON STOCK, $0.001 PAR VALUE","eventDate":"2026-03-31","reportingPerson":"Jeremy M. Levin","reportingCik":null,"personType":"IN","sharesOwned":8551502,"percentOfClass":4.5,"filedAt":"2026-05-14","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001104659-26-016662","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"ADAR1 Capital Management, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":9284166,"percentOfClass":6.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001104659-26-016662","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"ADAR1 Capital Management GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":9284166,"percentOfClass":6.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001104659-26-016662","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Daniel Schneeberger","reportingCik":null,"personType":"HC,IN","sharesOwned":9284166,"percentOfClass":6.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001315863-26-000096","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-01-22","reportingPerson":"Affinity Asset Advisors, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":12149166,"percentOfClass":9,"filedAt":"2026-01-29","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001315863-26-000096","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-01-22","reportingPerson":"Michael Cho","reportingCik":null,"personType":"IN,HC","sharesOwned":12149166,"percentOfClass":9,"filedAt":"2026-01-29","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001623632-26-000052","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"Ann C. Donahue","reportingCik":null,"personType":"IN","sharesOwned":7737166,"percentOfClass":5.94,"filedAt":"2026-01-08","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001623632-26-000052","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"J. Christopher Donahue","reportingCik":null,"personType":"IN","sharesOwned":7737166,"percentOfClass":5.94,"filedAt":"2026-01-08","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001623632-26-000052","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"Federated Hermes, Inc.","reportingCik":null,"personType":"HC","sharesOwned":7737166,"percentOfClass":5.94,"filedAt":"2026-01-08","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001623632-26-000052","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"Voting Shares Irrevocable Trust","reportingCik":null,"personType":"OO","sharesOwned":7737166,"percentOfClass":5.94,"filedAt":"2026-01-08","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001623632-26-000052","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"Thomas R. Donahue","reportingCik":null,"personType":"IN","sharesOwned":7737166,"percentOfClass":5.94,"filedAt":"2026-01-08","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0000902664-26-000036","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-01-02","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":6727209,"percentOfClass":5.1,"filedAt":"2026-01-05","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0000902664-26-000036","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-01-02","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":6727209,"percentOfClass":5.1,"filedAt":"2026-01-05","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0000902664-26-000036","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-01-02","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":6727209,"percentOfClass":5.1,"filedAt":"2026-01-05","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001346824-25-000079","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"OVID THERAPEUTICS INC.","ticker":"OVID","cusip":null,"securityClass":"Common Stock par value $0.001 per share","eventDate":"2025-12-11","reportingPerson":"RA Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":13259735,"percentOfClass":9.9,"filedAt":"2025-12-18","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001346824-25-000079","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"OVID THERAPEUTICS INC.","ticker":"OVID","cusip":null,"securityClass":"Common Stock par value $0.001 per share","eventDate":"2025-12-11","reportingPerson":"RA Capital Healthcare Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":13259735,"percentOfClass":9.9,"filedAt":"2025-12-18","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001346824-25-000079","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"OVID THERAPEUTICS INC.","ticker":"OVID","cusip":null,"securityClass":"Common Stock par value $0.001 per share","eventDate":"2025-12-11","reportingPerson":"Rajeev Shah","reportingCik":null,"personType":"HC,IN","sharesOwned":13259735,"percentOfClass":9.9,"filedAt":"2025-12-18","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001346824-25-000079","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"OVID THERAPEUTICS INC.","ticker":"OVID","cusip":null,"securityClass":"Common Stock par value $0.001 per share","eventDate":"2025-12-11","reportingPerson":"Peter Kolchinsky","reportingCik":null,"personType":"HC,IN","sharesOwned":13259735,"percentOfClass":9.9,"filedAt":"2025-12-18","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001315863-25-000859","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-11","reportingPerson":"Affinity Healthcare Fund, LP","reportingCik":null,"personType":"PN","sharesOwned":12149166,"percentOfClass":9,"filedAt":"2025-12-18","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001315863-25-000859","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-11","reportingPerson":"Affinity Asset Advisors, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":12149166,"percentOfClass":9,"filedAt":"2025-12-18","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001395064-25-000167","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-08","reportingPerson":"Takeda Pharmaceutical Company Limited","reportingCik":null,"personType":"CO","sharesOwned":8781996,"percentOfClass":12.3,"filedAt":"2025-12-09","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001395064-25-000167","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001636651","issuerName":"Ovid Therapeutics Inc.","ticker":"OVID","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-08","reportingPerson":"Takeda Pharmaceutical U.S.A., Inc.","reportingCik":null,"personType":"CO","sharesOwned":7000000,"percentOfClass":9.8,"filedAt":"2025-12-09","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"},{"accessionNo":"0001274173-25-000340","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636651","issuerName":"OVID THERAPEUTICS INC.","ticker":"OVID","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-28","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"IA,HC","sharesOwned":7114114,"percentOfClass":9.99,"filedAt":"2025-12-08","canonicalUrl":"https://xoomar.com/markets/stocks/ovid"}],"updatedAt":"2026-11-05T15:20:51.523Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/ovid","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}